Wang Jia-Wen, Feng Ying-Fa, Liu Jia-Hui
Department of Orthopedics, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Front Immunol. 2025 Jul 1;16:1629879. doi: 10.3389/fimmu.2025.1629879. eCollection 2025.
Malignant melanoma brain metastases (MBM) represent one of the deadliest complications of melanoma, with an incidence rate of 7.3%. Among patients with acral and mucosal melanoma, the cumulative 5-year incidence can reach 19.5%, accompanied by poor prognosis. The blood-brain barrier (BBB), an immunosuppressive central nervous system (CNS) microenvironment, and tumor immune evasion collectively limit the efficacy of traditional therapies. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), as critical immune checkpoints, play pivotal roles in the progression of MBM. This study systematically analyzes the synergistic mechanisms, clinical outcomes, and challenges of CTLA-4 and PD-1 combined blockade therapy in MBM. The findings indicate that this combination therapy leverages a "priming and boosting" biological mechanism: CTLA-4 blockade broadens T-cell responses during the initial activation phase, while PD-1 blockade sustains T-cell activity during the effector phase, significantly improving intracranial response rates (46%, compared to 20% for monotherapy). Furthermore, the combination therapy increases the CD8+/Treg ratio and promotes memory CD8+ T-cell formation, enabling durable antitumor immune surveillance. However, challenges such as a 54% incidence rate of grade 3-4 adverse events and suboptimal therapeutic regimens remain. To address these issues, this study proposes a multi-tiered adverse event management system, personalized risk assessment models, and treatment optimization strategies based on real-time monitoring and dynamic adjustments. Future directions include developing precision stratified therapies based on immunogenomics, exploring multi-target synergistic approaches, and implementing intelligent adverse event prediction and management systems to maximize therapeutic efficacy and minimize toxicity, providing more effective treatment for MBM patients.
恶性黑色素瘤脑转移（MBM）是黑色素瘤最致命的并发症之一，发病率为7.3%。在肢端和黏膜黑色素瘤患者中，5年累计发病率可达19.5%，且预后较差。血脑屏障（BBB）、免疫抑制性中枢神经系统（CNS）微环境和肿瘤免疫逃逸共同限制了传统疗法的疗效。细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和程序性细胞死亡蛋白1（PD-1）作为关键的免疫检查点，在MBM的进展中起关键作用。本研究系统分析了CTLA-4和PD-1联合阻断疗法在MBM中的协同机制、临床疗效及挑战。研究结果表明，这种联合疗法利用了一种“启动和增强”的生物学机制：CTLA-4阻断在初始激活阶段拓宽T细胞反应，而PD-1阻断在效应阶段维持T细胞活性，显著提高颅内反应率（46%，单药治疗为20%）。此外，联合疗法增加了CD8+/调节性T细胞（Treg）比例，促进记忆性CD8+T细胞形成，实现持久的抗肿瘤免疫监视。然而，仍存在3-4级不良事件发生率达54%以及治疗方案欠佳等挑战。为解决这些问题，本研究提出了一个基于实时监测和动态调整的多层不良事件管理系统、个性化风险评估模型及治疗优化策略。未来的方向包括基于免疫基因组学开发精准分层疗法、探索多靶点协同方法以及实施智能不良事件预测和管理系统，以最大化治疗效果并最小化毒性，为MBM患者提供更有效的治疗。
